Incidence Of Atrial Fibrillation Significantly Reduced By Atacand® Therapy In Heart Failure Patients

... New data published in the American Heart Journal show that Atacand® (candesartan cilexetil) is the first angiotensin receptor blocker (ARB) to significantly reduce the incidence of atrial fibrillation (AF) in a wide spectrum of heart failure patients, including those with preserved as well as reduced left ventricular systolic function, when added to contemporary therapy. [click link for full article] ...